Placeholder Banner

BIO Comments on FDA docket Standards for Future Opioid Analgesic Approvals and Incentives for New Therapeutics to Treat Pain and Addiction

November 18, 2019

Biotechnology Innovation Organization (BIO) comments on the FDA docket, Standards for Future Opioid Analgesic Approvals and Incentives for New Therapeutics to Treat Pain and Addiction. BIO also believes that risks associated with opioid therapies can be surmounted through further innovation on safe and effective analgesics with lower risks.

Download Full Comments Below
Comments on New Therapeutics to Treat Pain and Addiction
Discover More
The Biotechnology Innovation Organization is pleased to submit a statement for the record to the United States House of Representatives Committee on Agriculture hearing entitled, "Climate Change and the U.S. Agriculture and Forestry Sectors." BIO…
The Biotechnology Innovation Organization is pleased to submit a statement for the record to the United States House of Representatives Committee on Energy and Commerce Subcommittee on Environment and Climate Change hearing entitled, "Back in Action…
We encourage you to formally withdraw the proposed rule from the previous administration to remove IER, and to fully implement IER for the first time.  The International Entrepreneur Rule would allow world-class foreign entrepreneurs to launch…